Age- related macular degeneration (AMD) is the leading cause of acquired blindness. Several new treatment options became available in the past seven years. The purpose of this paper is to review these new treatment options. New treatment possibilities including agents blocking the effect of the vascular endothelial growth factor are summarized. Photodynamic therapy was the „gold standard” treatment for years and was found to be effective in reducing the risk of visual loss. Intravitreal injections of pegaptanib and ranibizumab may reduce macular edema and might result in gain of visual acuity.Introduction of anti-VEGF therapies multiplied the number of treatable patients and results are much better than before. Access to these new therapeutic options might be limited by the high prize of the drugs.